Endothelin-1 (Human)
ET-1 (Porcine, Canine, Rat, Mouse, Bovine)

4198-s 0.1 mg | 115.00 EUR
4198-v 0.5 mg | 285.00 EUR

Synthetic Product (disulfide bonds between Cys¹-Cys¹⁵ and Cys³-Cys¹¹)

Cys – Ser – Cys – Ser – Ser – Leu – Met – Asp – Lys – Glu – Cys – Val – Tyr – Phe – Cys – His – Leu – Asp – Ile – Ile – Trp

The purity is guaranteed to be higher than 99% by HPLC

Endothelin-1 (ET-1) is described as a biologicaly active peptide of 21 aminoacid residues, which contains 2 disulfide bridges. This endothelium-derived peptide shows high vasoconstrictor and proliferative attributes. Failures in the regulation process of Endothelin-1 (ET-1) may be one reason for hypertension and some other cardiovascular diseases.

The biological activity of Endothelin-1 is examined by the Division of Pharmacology, Peptide Institute, Inc.

References:

1. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto and M. Masaki, Nature, 332, 411 (1988) (Original)
2. A. Inoue, M. Yanagisawa, S. Kimura, Y. Kasuya, T. Miyauchi, K. Goto and T. Masaki, Proc. Natl. Acad. Sci. USA, 86, 2863 (1989) (Naming)
3. T.X. Watanabe, Y. Itahara, K. Nakajima, S. Kumagaye, T. Kimura and S. Sakakibara, J. Cardiovasc. Pharmacol., 17 (Suppl. 7), S5 (1991) (Pharmacology of Endothelin-1)

Links to publications that use our peptide Endothelin-1 | code 4198-s:

1. Blunted IgE-Mediated Activation of Mast Cells in Mice Lacking the Ca²⁺-Activated K⁺ Channel K_Ca3.1

ET-1 is distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Company, Ltd. and the National Institute of Advanced Industrial Scienence & Technology (AIST)